Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant novel coronavirus XBB.1.5 variant vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
Recombinant novel coronavirus XBB.1.5 variant vaccine is a viral vector vaccine designed to protect against COVID-19 caused by the SARS-CoV-2 XBB.1.5 variant. The specific version described in clinical trials (such as ChiCTR2300075626) utilizes a replication-defective adenovirus type 5 (Ad5) vector to deliver the genetic sequence of the XBB.1.5 spike protein. Developed by CanSino Biologics in collaboration with the Seventh Medical Center of PLA General Hospital, this vaccine is formulated for administration via inhalation. This route is intended to elicit mucosal immunity in the respiratory tract—the primary site of viral entry—in addition to systemic humoral and cellular immune responses. It is primarily positioned as a booster dose for adults who have previously completed a primary vaccination series.
- Brand names
- Convidecia Air
- Other names
- recombinant novel coronavirus XBB.1.5 variant vaccine (adenovirus type 5 vector)inhaled Ad5-vectored XBB.1.5 COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant novel coronavirus XBB.1.5 variant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant novel coronavirus XBB.1.5 variant vaccine.